Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now IOB - Delayed Quote • EUR Carmila S.A. (0QAP.IL) Follow Compare 17.04 -0.21 (-1.22%) At close: March 13 at 9:20:18 AM GMT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations CARMILA: Information Concerning the Total Number of Voting Rights and Share PARIS, March 13, 2025--Regulatory News: CARMILA (Paris:CARM): The Competition Authority Approves Carmila's Acquisition of Galimmo PARIS, March 13, 2025--Regulatory News: Carmila (Paris:CARM) acknowledges the decision of the French Competition Authority, which brings an end to the exemption period regarding the takeover of Galimmo’s shopping galleries, finalised today. Carmila: Changes to the Composition of the Board of Directors Following the Change in the Permanent Representative of PREDICA PARIS, February 24, 2025--Regulatory News: Predica, a director of Carmila (Paris:CARM), decided on 17 February 2025 to appoint Florence Habib-Deloncle, Head of Real Estate in Predica's Investment Department, as its new permanent representative on Carmila's Board of Directors, replacing Emmanuel Chabas. Carmila SA (CRMIF) Full Year 2024 Earnings Call Highlights: Strong Leasing Activity and ... Carmila SA (CRMIF) reports robust financial performance with significant net rental income growth and strategic initiatives driving future prospects. Carmila: Launch of a Share Buyback Program for €10 Million PARIS, February 12, 2025--Regulatory News: Carmila (Paris:CARM) has signed a cash share buyback mandate with an investment service provider for a maximum amount of €10 million. Carmila: 2024 Annual Results: Sustained Growth Driven by the Acquisition of Galimmo and Strong Leasing Momentum BOULOGNE-BILLANCOURT, France, February 11, 2025--Regulatory News: Carmila (Paris:CARM): Carmila: Resources Devoted to the Liquidity Contract as of 31 December 2024 PARIS, January 14, 2025--Regulatory News: At 31 December 2024, resources made available for the liquidity agreement concluded by Carmila (Paris:CARM) with Kepler Chevreux were the following: Carmila Will Publish Its 2024 Full-year Results on Tuesday, February 11, 2025, After Market Close PARIS, January 09, 2025--Regulatory News: Carmila (Paris:CARM) will publish its 2024 full-year results on Tuesday, February 11, 2025, after market close and will present the 2024 full-year results on Wednesday, February 12, 2025, at 09:00 am CET. Carmila: Third-quarter 2024 Financial Information PARIS, October 17, 2024--Regulatory News: Carmila (Paris:CARM): Successful Completion of Tender Offer on Carmila’s Bonds With €200,100,000 of Bonds Tendered PARIS, September 24, 2024--Regulatory News: Carmila (Paris:CARM) successfully completed its tender offer, announced on 16 September 2024, on the following series of existing notes: Carmila Successfully Issues Inaugural €300M 7-Year Green Bond, Paying a Fixed Annual Coupon of 3.875% PARIS, September 17, 2024--Regulatory News: Carmila (Paris:CARM) today issued its first green bond for a total amount of €300 million. With a maturity of just over seven years, the bonds fall due on 25 January 2032 and pay an annual coupon of 3.875%. The financing was raised at a spread of 160 basis points above the benchmark rate with no issue premium. Carmila Announces the Launch of a Tender Offer on Its Existing Notes Maturing in May 2027, March 2028, October 2028 and April 2029, and Announces Its Intention to Issue New Notes PARIS, September 16, 2024--Regulatory News: Carmila (Paris:CARM) announces today the launch of a tender offer on the following series of existing notes: Carmila: Information Concerning the Total Number of Voting Rights and Share, Provided Pursuant to Article L.233-8 II of the Code de commerce (French Commercial Code) and Article 223-16 of the Règlement général de l’Autorité des marchés financiers PARIS, September 09, 2024--Regulatory News: Carmila (Paris:CARM): Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended June 30, 2024, and highlighted recent business updates. Carmila: Closing of the Acquisition of a Stake of 7% of Galimmo SCA from Capimmo PARIS, July 25, 2024--Regulatory News: Carmila (Paris:CARM) announces completion of the acquisition of 7% of the share capital of Galimmo SCA for a total consideration of 27 million euros, or 11.93 euros per share. Carmila: 2024 Half-Year Financial Report Available PARIS, July 24, 2024--Regulatory News: Carmila (Paris:CARM) has made available to the public and filed with the French financial markets authority (Autorité des Marchés Financiers) its 2024 Half Year Financial Report. Carmila: 2024 Half-Year Results PARIS, July 24, 2024--Regulatory News: Carmila (Paris:CARM): Carmila: Resources Devoted to the Liquidity Contract as of 30 June 2024 PARIS, July 05, 2024--Regulatory News: At 30 June 2024, resources made available for the liquidity agreement concluded by Carmila (Paris:CA) with Kepler Cheuvreux were the following: Carmila: Closing of the Acquisition of Galimmo SCA PARIS, July 01, 2024--Regulatory News: Carmila (Paris:CARM) announces the closing of the acquisition of 93% of the share capital of Galimmo SCA for a total consideration of 272 million euros, or 9.02 euros per share. Carmila: Potential Stake Increase in Galimmo SCA to 99.9% PARIS, July 01, 2024--Regulatory News: On June 28, 2024, Carmila (Paris:CARM) granted to an entity managed by Primonial REIM France a put option to sell its entire 7% stake in Galimmo SCA, exercisable1 until July 30, 2024, for approximately €27 million (that is €11.93 per share). Performance Overview Trailing total returns as of 3/13/2025, which may include dividends or other distributions. Benchmark is CAC 40 Return 0QAP.IL CAC 40 YTD +6.70% +7.55% 1-Year +13.84% -2.45% 3-Year +36.58% +26.80%